Core Insights - The stock of Oupeng Vision experienced a decline of 1.82% on December 2, with a trading volume of 91.74 million yuan [1] - As of November 28, the number of shareholders for Oupeng Vision was 61,900, a decrease of 0.56% from the previous period [2] Financing and Margin Trading - On December 2, Oupeng Vision had a financing buy amount of 11.18 million yuan and a financing repayment of 10.30 million yuan, resulting in a net financing buy of 0.88 million yuan [1] - The total margin trading balance for Oupeng Vision reached 599 million yuan, with the financing balance accounting for 4.26% of the circulating market value, indicating a high level compared to the past year [1] Business Performance - For the period from January to September 2025, Oupeng Vision reported a revenue of 1.433 billion yuan, reflecting a year-on-year growth of 0.13%, while the net profit attributable to shareholders decreased by 15.41% to 442 million yuan [2] - The company has cumulatively distributed dividends of 949 million yuan since its A-share listing, with 576 million yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Oupeng Vision included several ETFs, with notable reductions in holdings from major shareholders such as Huabao Zhongzheng Medical ETF and Yifangda Growth Enterprise Board ETF [3]

证券日报网讯12月2日，欧普康视（300595）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东总人数为61877户。 ...

一、担保概述 欧普康视科技股份有限公司（以下简称"公司"）全资子公司欧普康视投资 有限公司（以下简称"欧普投资"）的控股子公司马鞍山梦戴维医疗科技有限公 司（以下简称"马鞍山梦戴维"，担保方）的控股子公司马鞍山康视眼科医院有 限公司（以下简称"马鞍山康视医院"，被担保方）拟向浦发银行合肥分行申请 总额不超过人民币 300 万元的授信额度，授信期限 1 年，马鞍山梦戴维同意为马 鞍山康视医院向上述合作银行申请总额不超过人民币 300 万元融资事项提供连 带责任保证担保。 证券代码：300595 证券简称：欧普康视 公告编号：2025-091 欧普康视科技股份有限公司 关于控股子公司为其子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等相关规定，本次担保事项属于上市公司控股子公司为上市公司合并报 表范围内的法人提供担保，已履行子公司内部审批程序，无需提交公司董事会、 股东会审议。 二、被担保方基本情况 1、基本情况 公司名称：马鞍山康视眼科医院有限公司 成立日期： ...

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Core Viewpoint - Oupeng Vision's stock price has shown fluctuations, with a recent increase of 2.04% to 16.04 CNY per share, despite a year-to-date decline of 14.09% [1] Group 1: Stock Performance - As of December 1, Oupeng Vision's stock price is 16.04 CNY, with a trading volume of 65.02 million CNY and a turnover rate of 0.61%, resulting in a total market capitalization of 14.36 billion CNY [1] - The stock has experienced a 1.84% increase over the last five trading days, a 3.57% decrease over the last 20 days, and a 10.86% decline over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Oupeng Vision reported a revenue of 1.433 billion CNY, reflecting a year-on-year growth of 0.13%, while the net profit attributable to shareholders decreased by 15.41% to 442 million CNY [2] - The company has distributed a total of 949.7 million CNY in dividends since its A-share listing, with 576 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of November 20, the number of shareholders for Oupeng Vision is 62,200, a decrease of 1.11% from the previous period, with an average of 10,743 circulating shares per shareholder, an increase of 1.12% [2] - Major institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and others, with notable reductions in holdings [3]

Core Insights - The company OPPLE Optoelectronics reported that as of November 20, 2025, the total number of shareholders is 62,226 [2] Company Summary - OPPLE Optoelectronics is actively engaging with investors through platforms to provide updates on shareholder statistics [2]

Core Viewpoint - The company has launched new functional eyewear products and has begun consolidating a recent acquisition, contributing to its financial performance in the third quarter [1] Group 1: Product Development - The company has introduced functional frame glasses and recently launched "Composite Control" frame glasses using lithography technology, which combines defocus reduction and contrast control features [1] - Sales of functional frame glasses are categorized under "frame glasses and other optical products and technical services revenue," with disclosures in periodic reports [1] Group 2: Acquisition Impact - The acquisition of Shangyue Qicheng has been included in the consolidated financial statements starting from September [1] - The contribution of this acquisition to the net profit in the third quarter is reported to be small [1]

Group 1 - The core viewpoint of the article highlights the financial status and operational structure of Opcon Vision, including significant share pledges and revenue breakdowns for 2024 [1] - As of the announcement date, Nanjing Outo has pledged approximately 68.3 million shares, accounting for 67.98% of its total holdings [1] - The projected revenue composition for Opcon Vision in 2024 is as follows: 56.18% from the rigid contact lens industry, 20.04% from the medical sector, 19.47% from other optometry and professional services, and 4.31% from non-optometry and other services [1] - The current market capitalization of Opcon Vision is 15.3 billion yuan [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025-090 欧普康视科技股份有限公司 关于持股5%以上股东部分股份质押和解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）的通知，获悉其 将持有公司股份 600 万股质押给华龙证券股份有限公司，并将前期质押给华龙证 券股份有限公司的 475 万股解除质押。现将具体情况公告如下： 一、股东股份质押及解除质押的基本情况 注：本公告中所涉数据的尾数差异或不符系四舍五入所致。 2、股份解除质押基本情况 3、股份累计被质押的情况 截至本公告披露日，南京欧陶所持质押股份累计情况如下： | 已质押股份 | 未质押股份 | 情况 | 情况 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

Market Overview - The medical device sector experienced a slight decline of 0.13% on November 11, with Danaher Biomedical leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Top Performers - Anxu Bio (688075) saw a closing price of 42.54, with an increase of 4.39% and a trading volume of 23,700 [1] - Nanwei Medical (688029) closed at 86.17, up 3.89% with a trading volume of 31,700 [1] - Yirui Technology (688301) closed at 109.90, increasing by 2.65% with a trading volume of 22,000 [1] Underperformers - Danaher Biomedical (920009) closed at 77.69, down 4.91% with a trading volume of 16,300 [2] - Ruimait (301367) closed at 86.41, down 4.32% with a trading volume of 18,600 [2] - Tianchen Medical (688013) closed at 52.68, down 3.59% with a trading volume of 26,900 [2] Capital Flow - The medical device sector saw a net outflow of 642 million yuan from institutional investors, while retail investors contributed a net inflow of 463 million yuan [2][3] - The top net inflows from retail investors were observed in Nanwei Medical (688029) with 46.22 million yuan, and Tianchen Medical (688013) with 24.78 million yuan [3]